An observational study in Obesity and Morbidly Obese, sponsored by Yongtao Sun. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Yongtao Sun · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.
Among the 603 studies in Obesity with a site in China, this one is the 92nd largest by enrollment of the 99 observational ones that give a count, is one of 41 that started in 2022, is one of 99 observational ones, and was the 487th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 41 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 120 across the 504 interventional studies, 320 across the 99 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 603 have an industry lead sponsor. The 10 most frequent:
Yongtao Sun is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Yongtao Sun has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
106 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 106 to your calendar (.ics) → With an account.
Among the 603 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: The SaCoVLM™ video laryngeal mask is a novel video-assisted device that integrates the functions of both a dual-channel laryngeal mask airway (LMA) and an intubating laryngeal mask airway (ILMA). At present, there are relatively few studies on awake airway management for obese patients who undergo laparoscopic sleeve gastrectomy (LSG). To evaluate the efficacy and safety of the SaCoVLM™ video laryngeal mask airway as an intubation conduit in morbidly obese patients undergoing laparoscopic sleeve gastrectomy.
Patients and methods: This single-arm prospective study evaluated the efficacy and safety of the SaCoVLM™ video laryngeal mask airway in 57 morbidly obese patients (BMI ≥35 kg/m²) undergoing LSG.
All anesthesiologists in this study underwent centralized training prior to trial initiation, with documented certification in protocol-specific procedures. No preoperative medications were administered to any patients. Upon entering the operating room, patients were positioned in a semi-fowler position, with intravenous access established. Standard monitoring protocols were implemented, including electrocardiography (ECG), heart rate (HR), non-invasive blood pressure (NIBP), pulse oximetry (SpO₂), end-tidal carbon dioxide (EtCO₂), and bispectral index (BIS), alongside radial artery catheterization for invasive blood pressure monitoring. All patients underwent awake insertion of the SaCoVLM™, with surgery completed under general anesthesia combining the video laryngeal mask and endotracheal intubation.
Immediately upon arrival in the operating room, patients were instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical anesthesia. Premedication included midazolam 2 mg and atropine 0.4 mg, followed by bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected, and under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described. The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform confirmed proper mask alignment, after which rapid anesthesia induction was initiated.
If suboptimal positioning occurred, the up-down maneuver, cricoid pressure, cuff pressure adjustment, fiberoptic bronchoscopy-guided intubation were applied for minor adjustments. Under direct video guidance, the endotracheal tube was gently advanced along the natural curvature of the airway. Successful intubation was defined by unimpeded tube passage, direct visualization of tracheal entry, and sustained EtCO₂ waveform. Following intubation, the breathing circuit was immediately connected, and bilateral lung auscultation confirmed symmetrical breath sounds before securing both the mask and endotracheal tube. Intraoperative fluid administration and vasoactive medications were adjusted based on vital signs, urine output, and physiological requirements.
Postoperatively, the endotracheal tube was removed under deep anesthesia, and the video laryngeal mask was retained for transfer to the post-anesthesia care unit (PACU). The laryngeal mask was removed only after patients regained adequate spontaneous respiration, demonstrated responsiveness to verbal commands, and met established extubation criteria.
The study population comprised adult patients aged over 18 years (with no upper age limit) diagnosed with morbid obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) ≥ 40 kg/m², or BMI ≥ 35 kg/m² accompanied by at least one significant obesity-related comorbidity
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study was a single-arm prospective study, so there was no grouping.
Device: SaCoVLM™ in Difficult Airways
As part of the awake airway management protocol initiated in the operating room, patients were first instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical oropharyngeal anesthesia. This was followed by intravenous administration of midazolam 2 mg and atropine 0.4 mg, and bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected. The posterior surface of the cuff was lubricated with a water-based surgical lubricant. Under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™ insertion. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described . The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform.
As part of the awake airway management protocol initiated in the operating room, patients were first instructed to hold 10 mL of dyclonine mucilage orally for approximately 10 minutes to achieve topical oropharyngeal anesthesia. This was followed by intravenous administration of midazolam 2 mg and atropine 0.4 mg, and bilateral ultrasound-guided superior laryngeal nerve block using 0.375% ropivacaine. A properly sized laryngeal mask was selected. The posterior surface of the cuff was lubricated with a water-based surgical lubricant. Under awake conditions, patients were instructed to open their mouths to facilitate SaCoVLM™ insertion. Optimal positioning was confirmed by visualization of complete glottic structures on the monitor screen. The glottic exposure grade was as we previously described. The cuff was inflated using a handheld manometer, and the mask was connected to the anesthesia machine. Clear glottic visualization on the monitor and the presence of a regular EtCO₂ waveform.
the first-time success rate of intubation after insertion of SaCoVLM™
Time frame: Within 10 minutes following SaCoVLM™ placement
Time to Successful SaCoVLM™ Insertion (seconds)
Time to successful insertion is measured in seconds as a continuous time-to-event variable. Successful insertion is defined as proper placement of the SaCoVLM™ with visible chest rise and a square-wave capnography trace. Shorter time indicates a better outcome (faster airway establishment). The primary metric reported will be the median insertion time with interquartile range, along with the proportion of successful insertions within 60, 90, and 120 seconds.
Time frame: From the start of device insertion into the mouth until the time of successful SaCoVLM™ placement with first confirmed ventilation, assessed up to 120 seconds. If insertion is not successful within 120 seconds, the event is censored at 120 seconds.
Number of SaCoVLM™ Insertion Attempts per Participant
An insertion attempt is defined as any entry of the SaCoVLM™ into the patient's mouth with the intention of placement, regardless of depth or success. Each withdrawal of the device from the mouth followed by re-entry counts as a new attempt. The total number of attempts required to achieve successful placement (confirmed by end-tidal CO₂ waveform) is recorded. Fewer attempts indicate a better outcome (easier insertion). The primary metric reported will be the mean (or median) number of attempts, the range, and the proportion of participants requiring 1, 2, or ≥3 attempts.
Time frame: From the first insertion attempt until successful SaCoVLM™ placement is achieved or until the procedure is abandoned, assessed during the initial airway management procedure (up to 120 seconds or a maximum of 3 attempts, whichever comes first).
the SaCoVLM™ glottic exposure grades
Time frame: Immediately after SaCoVLM™ placement
Oropharyngeal Leak Pressure (OLP) (cm H₂O)
OLP is measured by closing the adjustable pressure limiting valve of the anesthesia circuit while maintaining a fixed gas flow of 3 L/min. The airway pressure at which an audible leak occurs around the device (or the pressure at which the capnography waveform flattens) is recorded as the OLP in cm H₂O. Higher OLP indicates a better seal and is considered a better outcome (more effective supraglottic airway seal). The primary metric reported will be the mean (or median) OLP with standard deviation or interquartile range.
Time frame: Immediately after successful SaCoVLM™ insertion and before start of positive pressure ventilation (measured at a single time point: within 1 minute of confirmation of correct placement)
Proportion of Participants Requiring Any Airway Optimization Maneuver During SaCoVLM™ Placement
The airway optimization protocol includes predefined maneuvers to improve ventilation or seal when SaCoVLM™ placement is suboptimal (e.g., audible leak \>30 cm H₂O, absent capnography, or inability to ventilate). Recorded maneuvers may include: chin lift, jaw thrust, head extension/flexion, device rotation, partial withdrawal and reinsertion, or changing to a different size/type of supraglottic airway. The primary outcome metric is the proportion of participants requiring any optimization maneuver during the specified time frame. Secondary metrics include the number of different maneuvers used per participant and the specific maneuvers most frequently applied. No numerical scale is used; this is a descriptive/binary outcome (optimization required: yes/no). Fewer required maneuvers indicate a better outcome (easier device placement).
Time frame: During the initial airway management procedure, from the start of the first insertion attempt until successful ventilation is confirmed (assessed up to 120 seconds or a maximum of 3 attempts).
Incidence and Severity of Postoperative Sore Throat (POST) as Assessed by a 4-Point Scale
POST is measured using a 4-point categorical scale: 0 = no sore throat 1. = mild sore throat (complains only when asked) 2. = moderate sore throat (complains spontaneously) 3. = severe sore throat (hoarseness or difficulty swallowing) Minimum value = 0, maximum value = 3. Higher scores indicate a worse outcome (more severe sore throat). The primary metrics reported will be: Incidence = proportion of participants with any POST (score ≥1) at the specified time point Severity = mean (or median) score at each time point, plus the proportion with severe POST (score 3)
Time frame: At 72 hours after the end of surgery
Incidence and Severity of Postoperative Hoarseness as Assessed by a 4-Point Scale
Postoperative hoarseness is measured using a 4-point categorical scale: 0 = no hoarseness (voice normal) 1. = mild hoarseness (voice slightly different but able to speak without difficulty) 2. = moderate hoarseness (voice obviously changed, speaking with effort) 3. = severe hoarseness (voice barely audible or aphonic)
Time frame: At 24 hours after the end of surgery
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Adverse events (AEs) are defined according to \[specify system, e.g., Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or a standardized surgical complication list\]. AEs include, but are not limited to: hypoxia, bradycardia, hypotension, laryngospasm, bronchospasm, dental trauma, bleeding, and allergic reaction. Each AE is graded for severity (mild/moderate/severe) and relationship to the procedure. The primary metric reported will be the proportion of participants experiencing at least one AE during the specified time frame. Secondary metrics include the total number of AEs, type and frequency of specific AEs, and proportion of severe AEs. No scale is used for the primary binary outcome; severity grading follows CTCAE (Grade 1-5, where higher grade = worse outcome).
Time frame: From the end of surgery until 72 hours postoperatively
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — all IPD collected throughout the trial, only IPD used in the results publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: From May 2022 to May 2023, we included a total of 57 patients who were scheduled to undergo bariatric surgery.
Access criteria: Who Qualified researchers from academic, non-profit, or commercial institutions with an approved research proposal; regulatory authorities; and direct collaborators. What Anonymized IPD, data dictionary, protocol, SAP, and ICF summary. No direct or indirect participant identifiers. How Submit proposal via online portal. Independent review committee approval. Sign data use agreement (non-identification, non-commercial, no third-party sharing). Access via secure virtual research environment or encrypted download; time-limited (e.g., 12 months); audit logs kept.
Ran from May 2022 to primary completion in May 2023, 12 months.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 12 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yongtao Sun